Format

Send to

Choose Destination
PLoS One. 2017 Sep 27;12(9):e0185436. doi: 10.1371/journal.pone.0185436. eCollection 2017.

Ezrin expression combined with MSI status in prognostication of stage II colorectal cancer.

Author information

1
Department of Pathology, University of Turku, Kiinamyllynkatu 10, Turku, Finland.
2
Department of Pathology, Misurata Cancer Center, University of Misurata, Faculty of Dentistry, Department of Basic Sciences, Misurata, Libya.
3
Auria Biobank, University of Turku and Turku University Hospital, Kiinamyllynkatu 8, Turku, Finland.
4
Department of Pathology and Genome Scale Biology Research Program, University of Helsinki and HUSLAB, Helsinki University Hospital, Helsinki, Finland.
5
Department of Oncology, Turku University Hospital, Hämeentie 11, Turku, Finland.
6
Department of Pathology, Turku University Hospital, Kiinamyllynkatu 10, Turku, Finland.

Abstract

Currently used factors predicting disease recurrence in stage II colorectal cancer patients are not optimal for risk stratification. Thus, new biomarkers are needed. In this study the applicability of ezrin protein expression together with MSI status and BRAF mutation status were tested in predicting disease outcome in stage II colorectal cancer. The study population consisted of 173 stage II colorectal cancer patients. Paraffin-embedded cancer tissue material from surgical specimens was used to construct tissue microarrays (TMAs) with next-generation technique. The TMA-slides were subjected to following immunohistochemical stainings: MLH1, MSH2, MSH6, PMS2, ezrin and anti-BRAF V600E antibody. The staining results were correlated with clinicopathological variables and survival. In categorical analysis, high ezrin protein expression correlated with poor disease-specific survival (p = 0.038). In univariate analysis patients having microsatellite instabile / low ezrin expression tumors had a significantly longer disease-specific survival than patients having microsatellite stable / high ezrin expression tumors (p = 0.007). In multivariate survival analysis, the presence of BRAF mutation was associated to poor overall survival (p = 0.028, HR 3.29, 95% CI1.14-9.54). High ezrin protein expression in patients with microsatellite stable tumors was linked to poor disease-specific survival (p = 0.01, HR 5.68, 95% CI 1.53-21.12). Ezrin protein expression is a promising biomarker in estimating the outcome of stage II colorectal cancer patients. When combined with microsatellite status its ability in predicting disease outcome is further improved.

PMID:
28953975
PMCID:
PMC5617236
DOI:
10.1371/journal.pone.0185436
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center